Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petak, I.
Right arrow Articles by Houghton, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petak, I.
Right arrow Articles by Houghton, J. A.
Clinical Cancer Research Vol. 6, 4119-4127, October 2000
© 2000 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Pediatric Rhabdomyosarcoma Cell Lines Are Resistant to Fas-induced Apoptosis and Highly Sensitive to TRAIL-induced Apoptosis1

Istvan Petak, Leslie Douglas, David M. Tillman, Reka Vernes and Janet A. Houghton2

Division of Experimental Hematology, Department of Hematology-Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105

Seven pediatric rhabdomyosarcoma (RMS) cell lines were resistant to the induction of apoptosis via the Fas death receptor. In contrast, four of seven lines (RD, Rh1, Rh18, and Rh30) were highly sensitive to tumor necrosis factor-{alpha}-related apoptosis-inducing ligand (TRAIL). TRAIL induced apoptosis within 4 h and also reduced clonogenic survival, both reversible by caspase inhibitors. DR5 (but not DR4) was expressed at high level in all cell lines. Expression of the decoy receptors DcR1 and DcR2 did not correlate with TRAIL sensitivity. All RMS lines expressed the adapter molecule FADD, and six of seven expressed procaspase-8. Expression of the inhibitory proteins c-FLIPL and c-FLIPS was high in three TRAIL-sensitive (RD, Rh1, and Rh30) and two TRAIL-resistant (Rh28 and Rh41) lines. All RMS lines expressed Bid and procaspases-3, -6, -7, and -9. Procaspases-8 and -10 were highest in TRAIL-sensitive RMS (RD, Rh1, and Rh30), and procaspase-10 was not expressed in Rh18, Rh36, or Rh41. TRAIL induced loss of mitochondrial membrane potential in TRAIL-sensitive Rh1 but not in TRAIL-resistant Rh41 cells. There was no correlation between expression of members of the Bcl-2 family (Bcl-2, Bcl-xL, Bax, and Bak) and TRAIL sensitivity. TRAILsensitive Rh18 expressed procaspase-8 in the absence of procaspase-10 and c-FLIP, and procaspase-10 was not detected in TRAIL-resistant Rh41 in the presence of procaspase-8 and c-FLIP. Data suggest that caspase-8 may be sufficient to deliver the TRAIL-induced apoptotic signal in the absence of both caspase-10 and c-FLIP (Rh18) but not in the presence of c-FLIP (Rh41). In RD, Rh1, and Rh30, the presence of c-FLIP may require amplification of the apoptotic signal via caspase-10.




This article has been cited by other articles:


Home page
JCOHome page
A. Ashkenazi, P. Holland, and S. G. Eckhardt
Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
J. Clin. Oncol., July 20, 2008; 26(21): 3621 - 3630.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
P-Y Fong, W-C Xue, H Y S Ngan, P-M Chiu, K Y K Chan, S W Tsao, and A N Y Cheung
Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study
J. Clin. Pathol., February 1, 2006; 59(2): 179 - 183.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
I. H. Engels, G. Totzke, U. Fischer, K. Schulze-Osthoff, and R. U. Janicke
Caspase-10 Sensitizes Breast Carcinoma Cells to TRAIL-Induced but Not Tumor Necrosis Factor-Induced Apoptosis in a Caspase- 3-Dependent Manner
Mol. Cell. Biol., April 1, 2005; 25(7): 2808 - 2818.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
T. Matsuda, A. Almasan, M. Tomita, J.-n. Uchihara, M. Masuda, K. Ohshiro, N. Takasu, H. Yagita, T. Ohta, and N. Mori
Resistance to Apo2 Ligand (Apo2L)/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Apoptosis and Constitutive Expression of Apo2L/TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines
J. Virol., February 1, 2005; 79(3): 1367 - 1378.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. S. Merchant, X. Yang, F. Melchionda, M. Romero, R. Klein, C. J. Thiele, M. Tsokos, H. U. Kontny, and C. L. Mackall
Interferon {gamma} Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing's Sarcoma
Cancer Res., November 15, 2004; 64(22): 8349 - 8356.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Izeradjene, L. Douglas, A. Delaney, and J. A. Houghton
Influence of Casein Kinase II in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Rhabdomyosarcoma Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6650 - 6660.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Guo, C. Sigua, J. Tao, P. Bali, P. George, Y. Li, S. Wittmann, L. Moscinski, P. Atadja, and K. Bhalla
Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells
Cancer Res., April 1, 2004; 64(7): 2580 - 2589.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. M. Tillman, K. Izeradjene, K. S. Szucs, L. Douglas, and J. A. Houghton
Rottlerin Sensitizes Colon Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis via Uncoupling of the Mitochondria Independent of Protein Kinase C
Cancer Res., August 15, 2003; 63(16): 5118 - 5125.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Uno, T. Inukai, N. Kayagaki, K. Goi, H. Sato, A. Nemoto, K. Takahashi, K. Kagami, N. Yamaguchi, H. Yagita, et al.
TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells
Blood, May 1, 2003; 101(9): 3658 - 3667.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Cinatl Jr., J. Cinatl, M. Michaelis, H. Kabickova, R. Kotchetkov, J.-U. Vogel, H. W. Doerr, T. Klingebiel, and P. H. Driever
Potent Oncolytic Activity of Multimutated Herpes Simplex Virus G207 in Combination with Vincristine against Human Rhabdomyosarcoma
Cancer Res., April 1, 2003; 63(7): 1508 - 1514.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.